Abstract
Bax inhibitor-1 (BI-1) is an evolutionarily-conserved endoplasmic reticulum protein. The expression of BI-1 in mammalian cells suppresses apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 family. BI-1 has been shown to be associated with calcium (Ca2+) levels, reactive oxygen species (ROS) production, cytosolic acidification, and autophagy as well as endoplasmic reticulum stress signaling pathways. According to both in vitro and clinical studies, BI-1 promotes the characteristics of cancers. In other diseases, BI-1 has also been shown to regulate insulin resistance, adipocyte differentiation, hepatic dysfunction and depression. However, the roles of BI-1 in these disease conditions are not fully consistent among studies. Until now, the molecular mechanisms of BI-1 have not directly explained with regard to how these conditions can be regulated. Therefore, this review investigates the physiological role of BI-1 through molecular mechanism studies and its application in various diseases.
Keywords: Bax inhibitor-1, ER stress, lysosome, reactive oxygen species, unfolded protein response.
Current Molecular Medicine
Title:The Characteristics of Bax Inhibitor-1 and its Related Diseases
Volume: 14 Issue: 5
Author(s): B. Li, R.K. Yadav, G.S. Jeong, H.-R. Kim and H.-J. Chae
Affiliation:
Keywords: Bax inhibitor-1, ER stress, lysosome, reactive oxygen species, unfolded protein response.
Abstract: Bax inhibitor-1 (BI-1) is an evolutionarily-conserved endoplasmic reticulum protein. The expression of BI-1 in mammalian cells suppresses apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 family. BI-1 has been shown to be associated with calcium (Ca2+) levels, reactive oxygen species (ROS) production, cytosolic acidification, and autophagy as well as endoplasmic reticulum stress signaling pathways. According to both in vitro and clinical studies, BI-1 promotes the characteristics of cancers. In other diseases, BI-1 has also been shown to regulate insulin resistance, adipocyte differentiation, hepatic dysfunction and depression. However, the roles of BI-1 in these disease conditions are not fully consistent among studies. Until now, the molecular mechanisms of BI-1 have not directly explained with regard to how these conditions can be regulated. Therefore, this review investigates the physiological role of BI-1 through molecular mechanism studies and its application in various diseases.
Export Options
About this article
Cite this article as:
Li B., Yadav R.K., Jeong G.S., Kim H.-R. and Chae H.-J., The Characteristics of Bax Inhibitor-1 and its Related Diseases, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603101113
DOI https://dx.doi.org/10.2174/1566524014666140603101113 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic Recent Advances in Anesthetic Management (Executive Guest Editors: Ehab Farag and D. John Doyle)]
Current Pharmaceutical Design BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Current Drug Safety Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Circulating Exosomes and Their Role in Stroke
Current Drug Targets Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Current Pediatric Reviews Editorial: Metabolic and Hormonal Alterations in Neuro-Psychiatric Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Expression Profiles of Long Noncoding and Messenger RNAs in Epicardial Adipose Tissue-Derived from Patients with Coronary Atherosclerosis
Current Vascular Pharmacology Fetal and Early-Postnatal Developmental Patterns of Obese-Genotype Piglets Exposed to Prenatal Programming by Maternal Over- and Undernutrition
Endocrine, Metabolic & Immune Disorders - Drug Targets The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics A Prospective Study on the Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in the Indian Population
Current Cancer Therapy Reviews Long-term Effects of Pre and Postnatal Food Restriction in Mechanical and Structural Properties of Rat Femur
Current Nutrition & Food Science Erythropoietin and Oxidative Stress
Current Neurovascular Research Structural Insight into PPARγ Ligands Binding
Current Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Small Molecules Antileishmanials: A Review
Letters in Drug Design & Discovery The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy
Current Drug Targets Comparison of Different Uses of Cyclophosphamide in Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Biofunctional Beverage: Antihyperglycemic Effect of Green Tea in Alloxan Induced Diabetic Rabbits
Current Bioactive Compounds